Inventage Lab is a leading South Korean biotechnology company specializing in advanced drug delivery platforms based on proprietary microfluidics technology. Listed on KOSDAQ, the company is dedicated to addressing critical challenges in drug formulation and delivery across multiple therapeutic modalities, including small molecules, peptides, and biologics.

The company's core technology portfolio includes four proprietary platforms: DrugFluidic®, a microsphere-based long-acting injectable (LAI) platform enabling monthly to quarterly sustained release for small molecules and peptides;
BioFluidic™, a subcutaneous delivery platform designed to convert IV biologics into patient-friendly SC formulations; GeneFluidic®/HANDYGENE®, an LNP-based mRNA delivery platform with integrated CDMO capabilities.

Inventage Lab has established strategic partnerships with leading pharmaceutical companies globally. The company's co-development programs span multiple therapeutic areas including metabolic disease, substance use disorder, and veterinary health. Additional collaborations include protein biologics formulation development and platform-based joint development initiatives with other major pharmaceutical companies.

Inventage Lab continues to expand its global presence and partnership network. The company's headquarters and GMP manufacturing facilities are located in South Korea, with ongoing clinical programs in Korea, Australia, and planning for additional territories.